EA
IOVA icon

Emerald Acquisition’s Iovance Biotherapeutics IOVA Stock Holding History

Emerald Acquisition’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-40,409
Closed -$327K – 3009
2016
Q2 		$327K Buy
+40,409
New +$254K ﹤0.01% 2615

Other funds holding IOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Acquisition's IOVA Position: Q3 2016 in Review

Emerald Acquisition sold out of Iovance Biotherapeutics (IOVA) in Q3 2016, closing a stake of 40,409 shares — an estimated $327K sold.

Emerald Acquisition first reported a position in IOVA in Q2 2016 and held it in 1 quarter. The position peaked at $327K in Q2 2016. 93 funds tracked by Wall St. Rank hold IOVA as of Q3 2016.

  • Emerald Acquisition reported no remaining Iovance Biotherapeutics position as of Q3 2016 after selling out during the quarter.
  • Emerald Acquisition sold 40,409 Iovance Biotherapeutics shares in Q3 2016, an estimated $327K.
  • Emerald Acquisition first reported a position in Iovance Biotherapeutics in Q2 2016 and held it in 1 quarter.
  • Emerald Acquisition's Iovance Biotherapeutics position peaked at $327K in Q2 2016.
  • 93 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.